{"id":616883,"date":"2022-09-16T22:26:01","date_gmt":"2022-09-16T22:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=616883"},"modified":"2022-09-16T22:26:01","modified_gmt":"2022-09-16T22:26:01","slug":"diffuse-large-bcell-lymphoma-dlbcl-market-to-grow-at-a-substantial-growth-rate-by-2032-key-companies-adc-therapeuticssobi-zynlonta-kitegilead-yescarta-genmab-epcoritamab","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diffuse-large-bcell-lymphoma-dlbcl-market-to-grow-at-a-substantial-growth-rate-by-2032-key-companies-adc-therapeuticssobi-zynlonta-kitegilead-yescarta-genmab-epcoritamab_616883.html","title":{"rendered":"Diffuse Large B-cell Lymphoma (DLBCL) Market to Grow at a Substantial Growth Rate by 2032 | Key Companies – ADC Therapeutics\/Sobi (ZYNLONTA), Kite\/Gilead (Yescarta), Genmab (Epcoritamab)"},"content":{"rendered":"
\n
\"Diffuse<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight\u2019s assessment, globally, about 80+ key pharma and biotech companies are working in the Diffuse Large B-cell Lymphoma (DLBCL) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n

DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diffuse Large B-cell Lymphoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Diffuse Large B-cell Lymphoma market<\/strong> report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Diffuse<\/p>\n

Diffuse Large B-cell Lymphoma (DLBCL): An Overview<\/strong><\/p>\n

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal center & post germinal center B-cells.<\/p>\n

Currently, the primary challenges in the research for DLBCL are to identify molecular subsets accurately and to determine if specific chemotherapy platforms and targeted agents offer the differential benefit with the ultimate goal of maximizing initial cure rates to improve long-term survival while minimizing toxicity.<\/p>\n

Consequently, some of the targeted therapies and cell therapies have already been approved for the treatment of DLBCL, while many are in the clinical stage of development which has demonstrated excellent initial outcomes and are in the process of further clinical evaluation.<\/em><\/p>\n

Diffuse Large B-cell Lymphoma (DLBCL) Market Key Facts<\/strong><\/p>\n

• The total incident cases of DLBCL in the 7MM were assessed to be 71,045<\/strong> in 2020 and are expected to increase by 2032.<\/em><\/p>\n

• Among the EU5 countries, Germany<\/strong> had the highest incident population of DLBCL, with 7,675 cases<\/strong>, followed by the United Kingdom<\/strong> and France<\/strong>, while Spain<\/strong> had the lowest incident cases in 2020.<\/em><\/p>\n

• Japan<\/strong> had 9,788 cases<\/strong> for DLBCL in 2020, which accounted for ~14%<\/strong> of the total 7MM patient population of DLBCL.<\/em><\/p>\n

• DLBCL cases most commonly affect middle-aged and older adults. In comparison, they are relatively less common in children and young adults. <\/em><\/p>\n

Diffuse Large B-cell Lymphoma (DLBCL) Market<\/strong><\/a><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Diffuse Large B-cell Lymphoma market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.<\/p>\n

The report details the Diffuse Large B-cell Lymphoma market trend<\/strong> for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n

Diffuse Large B-cell Lymphoma (DLBCL) Epidemiology<\/strong><\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.<\/p>\n

Diffuse Large B-cell Lymphoma (DLBCL) Epidemiology Segmentation –<\/strong><\/p>\n